COLL vs PATH
Collegium Pharmaceutical Inc (COLL) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the COLL and PATH stock pages for the full models.
Not investment advice.